Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with Stress Urinary Incontinence using a Novel Regenerative Cell Therapy

Zurich, Switzerland, September 8, 2022 -- Muvon Therapeutics AG, an innovative clinical-stage biotechnology company announced results from a Phase I clinical trial. This first study evaluating a proprietary cell therapy platform demonstrated the safety, feasibility and potential efficacy of autologous skeletal muscle injections into the bladder sphincter of women suffering from Stress Urinary Incontinence with the goal of naturally restoring strength and function over 6 months.

Stress Urinary Incontinence (SUI) is defined as the complaint of any involuntary loss of urine on effort or physical exertion. It is a highly prevalent and untreated disorder which affects over 200 million people worldwide. It has a severe impact on both physical and psychological health and imposes a high burden on quality of life on affected individuals. Up to 60 percent of women above the age of 40 are affected and twice as often as men following prostate surgery. All existing treatment options from conservative to interventional including Kegel exercises, bulking agents and surgical devices exhibit drawbacks ranging from limited, short-term relief to potentially serious adverse events.

Professor Daniel Eberli, MD PhD, the sponsor-investigator and Dr Florian Schmid, MD PhD, the co-investigator of this study from the Department of Urology at the University Hospital Zurich stated:

"We believe this cell therapy platform represents a truly unique mechanism to repair damaged sphincter muscle tissue using the body's own precursor cells without the need for any foreign body placement through surgery. We will be presenting our findings at the International Continence Society Annual Meeting (ICS) in Vienna, on Friday, September 9 at 11.45-11.52 in Hall D. Furthermore, we have submitted a manuscript reporting our complete findings to a leading scientific peer-reviewed journal."

ICS 2022 Abstract: #275 Transurethral Injection of Autologous Muscle Precursor Cells for the Treatment of Female Stress Urinary Incontinence – a Prospective and Randomized Phase I Clinical Trial

Dr Deana Mohr, CEO of Muvon Therapeutics added: "We have cleared the first major hurdle in our development program in the field of regenerative therapies where there is an extremely high unmet need and limited satisfaction with solutions. These results underscore rigorous pre-clinical testing and our ability to successfully extract muscle precursor cells from a patient, expand them in GMP laboratory conditions and inject into the sphincter muscle."

Dr John Coelho, Medical Affairs Leader noted: "The results of the Phase I feasibility study show that administration of this cell therapy is safe and well tolerated. We can now advance to the larger, adequately powered Phase II study with the intent of bringing a transformative option to patients with stress urinary incontinence."

Summary of Results:

Ten female patients were included in the study, of which 9 received treatment and completed all follow-up visits during the study period. Patients had a median age of 45 years and a median BMI of 24kg/m².

Importantly, the median functional urethral length (FUL) under stress was significantly longer with 30mm at 6 months follow-up compared to 25mm baseline (95% CI: 2.5 to 7, p = 0.009). 

Median maximum bladder capacity was 610ml at baseline and 670ml at follow-up (95% CI: -45 to 140, p = 0.343). 

Finally, quality of life (QoL) questionnaires showed an improvement ICIQ-scores from median 7 points at baseline to median 4 points at 6 months follow-up (95% CI: -7 to -2.5, p-value = 0.035). 

Eight adverse events (AEs) were registered, of which 2 were potentially related to the treatment. One urinary tract infection (UTI) was diagnosed three weeks after injection and was successfully treated with a single dose of oral Fosfomycin. No serious AEs were registered. 

The evaluation using magnetic resonance imaging of the pelvis revealed no evidence of aberrant tissue formation or necrosis and moreover showed increase in muscle volume in all patients. 

For more information, please contact:

Dr Deana Mohr, CEO

info@muvon-therapeutics.ch

About Muvon Therapeutics AG:

Muvon Therapeutics, a clinical-stage company, was founded as a spin-off from the University of Zurich. Muvon Therapeutics is dedicated to the discovery and development of personalized regenerative treatments as the primary standard of care. Our goal is to help the millions of patients suffering from serious debilitating diseases regain control of their lives by offering them minimally invasive treatment for regeneration of skeletal muscle. For more information about Muvon Therapeutics, please visit: About Us | Muvon Therapeutics | Switzerland

Microquest EMR First to Integrate PrescribeIT® V5.0

TORONTO, Sept. 8, 2022 /CNW/ - Canada Health Infoway (Infoway) and Microquest are pleased to announce that Microquest's Healthquest electronic medical record (EMR) has become the first EMR to integrate V5.0 of Infoway's PrescribeIT^® electronic prescribing service, and close to 1,200 prescribers in Alberta will soon benefit from the new features.

PrescribeIT^® enables prescribers to send prescriptions and renewals electronically to a patient's pharmacy of choice, resulting in more efficient patient care, enhanced safety and improved communication between clinicians.

In direct response to customer feedback, PrescribeIT^® V5.0 offers a number of improvements to the functionality of the service, including:

• Enhancements to streamline prescriber e-renewal responses and more closely align them to prescriber workflows;                                
• Functionality to reduce confusion with dispense notifications when multiple medications are dispensed for a single prescription;
• Enhanced and automated search and matching functionality to enable prescribers to efficiently update local pharmacy records within the prescribers' EMRs; and
• A streamlined log-in feature to enable prescribers to enter two-factor authentication when they log into their EMR instead of at the time of prescribing.

"We are very excited to integrate PrescribeIT^® V5.0 into our Healthquest EMR because it's essential to ensure that our EMR is always current and at the forefront of technology," said Brandon Blanck, Vice President and Chief Operating Officer, Microquest Inc. "V5.0 will offer tremendous benefits to our hundreds of prescribers and clinics in Alberta, and we look forward to a mass deployment in the near future."

"We are thrilled to work with Microquest to ensure that its EMR is leading the way in integrating new and improved features of our PrescribeIT^® service," said Jamie Bruce, Executive Vice President, Infoway. "We are also grateful to all prescribers and EMR vendors who have provided us with such valuable insights and suggestions to improve the functionality of PrescribeIT^®. We will continue to seek and respond to this feedback to ensure that PrescribeIT^® always meets their needs and makes the e-prescribing process as convenient and efficient as possible."

PrescribeIT^® is now live in 677 communities in six provinces (Ontario, Alberta, New Brunswick, Saskatchewan, Newfoundland and Labrador and Manitoba), and Infoway is working with other provinces and territories to develop roll-out plans. More than 10,000 prescribers and 6,000 pharmacy sites are enrolled in the service. See the interactive locator map.

About Microquest

Operating since 1993, Microquest is the developer of Alberta's premier electronic medical record (EMR) software, Healthquest. We pride ourselves on our customer service, offering superior products and unrivaled support to more than 430 EMR clinics and 1,200 prescribers across Alberta. Microquest enjoys being innovative within the health care space and works tirelessly to ensure we are fully integrated with the latest opportunities available, such as PrescribeIT^® V5.0. Microquest is a privately held company, owned and operated within Alberta with a focus purely on health care software. Visit us online at https://www.microquest.ca.

About Canada Health Infoway

At Canada Health Infoway (Infoway) we believe a more connected and collaborative system is a healthier system, and we work with governments, health care organizations, clinicians and patients to make health care more digital. We're working to ensure that everyone is able to access their personal health information, book appointments, get prescriptions, view lab test results and access other health services, online. We're working with our partners to transform the health system because we know that digital in health can be as transformative as digital has been in other aspects of our lives. We're an independent, not-for-profit organization funded by the federal government. Visit us online at www.infoway-inforoute.ca.

About PrescribeIT®

Canada Health Infoway is working with Health Canada, the provinces and territories, and industry stakeholders to develop, operate and maintain the national e-prescribing service known as PrescribeIT^®. PrescribeIT^® will serve all Canadians, pharmacies and prescribers and provide safer and more effective medication management by enabling prescribers to transmit a prescription electronically between a prescriber's electronic medical record (EMR) and the pharmacy management system (PMS) of a patient's pharmacy of choice. PrescribeIT^® will protect Canadians' personal health information from being sold or used for commercial activities. Visit www.PrescribeIT.ca.

Health Association Nova Scotia announces partnership with Indigenous Treaty Partners

HALIFAX, NS, Sept. 8, 2022 /CNW/ - Health Association Nova Scotia (HANS), today announced a new service offering, in collaboration with Indigenous Treaty Partners (ITP). Indigenous Treaty Partners will provide insightful Indigneous cultural awareness training with a focus on diversity, equity, and inclusion in the workplace, for all HANS members—at no charge.

"Our for-profit subsidiary, Igility Services, provides an annual dividend to HANS to make this training possible," said Mary Lee, CEO of HANS and Igility Services, "We are an industry driven by people—and that's why we recognize the need to build our workplace capacity with First Nations leaders and communities. We sought input from our members and they indicated the need for this support."

The announcement was made at a staff recognition event, held earlier today. HANS established its subsidiary, Igility Services, to benefit their members with the goal to redirect additional revenues back to HANS, to help reduce the costs of services or support indirect benefits to their membership.

Houston Barnaby, Partner with ITP added, "Our goal is to bridge the gap between organizations who want to work with Indigenous communities, to bring people to a place of competence and confidence, with the hopes of rebuilding our Nations together in the spirit of Peace and Friendship."

About Indigenous Treaty Partners

The Indigenous Treaty Partners offer a robust Indigenous cultural awareness training program that works to educate and indigenize Corporate Canada for Board of Directors, Corporate Directors, Management, and general staff. For more information, please visit: https://www.treatypartners.ca/

About Igility Services/ Health Association Nova Scotia

A subsidiary of Health Association Nova Scotia, Igility provides services to drive business efficiency. Through our executive search services, safe patient handling solutions, business advisory services, and financial advisory services, we help organizations streamline their processes, so they can focus on their core purpose and focus on what matters most. For more information, please visit: https://igility.services/ 

Health Association Nova Scotia is a not-for-profit, non-government, membership-based association with 60 years' experience in delivering exceptional human resource shared services, innovative clinical engineering service solutions, policy support and expertise our members can count on. Our membership includes more than 130 organizations from across the health continuum, including the NSH, the IWK Health Centre, the majority of licensed nursing homes and publicly funded home care agencies in Nova Scotia, the province's Adult Residential Centres/Regional Rehabilitation Centres, and other health-related organizations.  https://www.healthassociation.ns.ca/

SOURCE HEALTH ASSOCIATION NOVA SCOTIA

Samaritan Ministries members offer prayer and financial support for young members with cancer 

Over the past five years, ministry members have shared more than $7 million for young ones’ cancer needs 

PEORIA, Ill. — Childhood Cancer Awareness Month is an opportunity to reflect on the challenges and needs for families facing that difficult situation. Members of Samaritan Ministries International(Samaritan) send shares to fellow member families who are dealing with a number of health issues — sometimes a child’s cancer diagnosis — giving spiritual encouragement and financial help for those needs. 

“Samaritan Ministries members come alongside families struggling with childhood cancer treatments and diagnoses and connect them with fellow believers who can help share their burdens,” said Anthony Hopp, Samaritan’s chief purpose officer.

“Again and again, our members have comforted other families with notes of sympathy and prayers for healing,” Hopp said. “Jesus is the Great Healer in all matters, and we do our best to carry out His work.”

Cancer is consistently the top health care need that Samaritan members share. From 2017 to 2021, members shared $7,003,217 in cancer-related needs for members under 18.   

“Cancer at any stage of life can be devastating, but it’s especially soul-wrenching when it happens to a child,” Hopp said. “Our hearts go out to those children and their families as we observe Childhood Cancer Awareness Month.” 

Samaritan gives people of Biblical faith an effective, Bible-driven health care community in which approximately $30 million in medical needs is shared person to person every month. Over the past 27 years, Samaritan Ministries members have aided thousands of families and individuals, sharing more than $3 billion in needs while also praying for and encouraging fellow members through personal notes, cards and letters.

One Samaritan member family from Tennessee recently expressed their gratitude for fellow members’ support as their 6-year-old son was finishing more than two years of treatment for leukemia.

“Thank you all for being part of our family’s support system as we walked this road with Gabe,” Jill wrote in the Samaritan Ministries Community Facebook Group. “Being a Samaritan member was a huge blessing to us during this process.

“We are so proud of Gabe and his joyful spirit even during some very challenging few years. Walking beside him as his mama really has been an honor. Thank God for sustaining us through these last two years and thank God for sweet Gabriel Robert’s life. We can't wait to see what is in store for this child.”

Other Samaritan members experiencing cancer also wrote or called in to share their experiences:

Steve and Stacie from Kansas wrote:

“We had to walk a cancer journey and Samaritan and the supporting members were there for us every step of the way.” 

Stephen and Amy from South Dakota shared:

“We are so thankful for all the loving and encouraging notes we received with so many of the shares. Amy is recovering well, and they believe the cancer they knew of has been removed. Again, we are so grateful to all the help we received and all the prayers.” 

Wallace and Christina, who live in New Jersey, said: 

“Thank you for everything you do for all of us as members. This ministry is such a blessing and my family has been blessed to be a part of it for a year now. God is so good! We are so happy to be a part of something that glorifies God. Health insurance does not do that. Because of a share for my husband, we were introduced to a member of our local community. Her son is battling cancer and we have been praying for each other. We appreciate everything Samaritan does and what it represents! All glory to God!”

Samaritan Ministries currently has a membership of 282,541 individuals from 83,700 households.

Samaritan has no limited enrollment period. Government exchange-based health insurance requires signups to occur only during open enrollment periods unless one qualifies for a special enrollment period due to a “life event” such as losing coverage, getting married, moving, or having a baby.

Samaritan Ministries health care sharing offers additional advantages:

• No network restrictions. When medical care is needed, Samaritan members choose the health care provider, hospital, and pharmacy that work best for them.
• The direct-sharing approach allows members to not only help fellow believers with their medical financial needs but to pray for and connect with them on a regular basis.
• Monthly shares are hundreds of dollars less per month than insurance.

Learn more about Samaritan Ministries International here; visit the Samaritan website at www.samaritanministries.org, or follow the ministry on Facebook, Instagram or Twitter.   

Origin Therapeutics Announces New Director

Vancouver, B.C., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (CSE: ORIG) (the “Company” or “Origin Therapeutics”), an actively managed, psychedelics industry-focused investment issuer, is pleased to announce the election of Michael Galego as a new director of the Company. Pursuant to the Company’s articles, the board of directors is permitted to increase the size of the board by one-third of the number of current directors between annual meetings of the shareholders.

Michael Galego is an executive, lawyer and corporate director with extensive M&A, corporate finance and governance experience. Mr. Galego is currently CEO of Apolo Capital Advisory Corp. and sits on the board of directors of several public and private companies. Mr. Galego has been the co-founder of several businesses, including ICC Labs, Terrace Global and several other TSXV listed companies.

Mr. Galego was previously the CEO of the Stronach Group, Agricultural Division and an advisor to Mr. Frank Stronach. Mr. Galego commenced his career at Osler, Hoskin & Harcourt LLP in the Business Law Department. He subsequently was legal counsel to several public and private companies operating in the resource sector in South America. He was previously legal counsel to Pacific Rubiales Energy Corp., CGX Energy Inc., Medoro Resources Corp., Alange Energy Inc., Gran Colombia Corp. and involved in more than $3 billion in equity transactions and more than $5 billion in debt financings. Mr. Galego was a co-founder and director of ICC Labs until its sale to Aurora Cannabis Inc. in November 2018.

Mr. Galego holds an LLB. From the University of Windsor and a B.A. from York University. Mr. Galego is also a graduate of the Harvard Business School High Potentials Leadership Program. Mr. Galego was named to Lexpert’s “Top 40 under 40”.

About Origin Therapeutics

Origin Therapeutics is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector.

Learn more at www.originpsychedelics.com and follow the Company on LinkedIn, Twitter, and Instagram

For Further Information:

Kelvin Lee
Chief Financial Officer 
Origin Therapeutics Holdings Inc.

www.originpsychedelics.com info@originpsychedelics.com

Forward-Looking Information and Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Except as required by applicable law, the Company does not intend to update these forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Transformative Dementia and Alzheimer’s treatment

company Kurve Therapeutics launches $50 million

equity crowdfunding raise 

Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise.

Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases.

Caption: Transformative Dementia and Alzheimer’s treatment company Kurve Therapeutics launches $50 million equity crowdfunding raise 

Diseases like Dementia and Alzheimer's afflict millions of people across the globe, while over 1 billion people worldwide – 1 in 6 – suffer from a neurological disease. Yet, Healthcare sectors lack effective, disease-modifying treatments.

Kurve Therapeutic's patented intranasal drug delivery technology, Controlled Particle Dispersion® (CPD), has been shown to bypass the blood-brain barrier, delivering 30x more medication directly to the brain than infusions.

Marc Giroux, Kurve Therapeutics CEO and founder said: "An IV infusion manages to deliver one-tenth of 1% through the blood-brain barrier. We have measured our success at 30 times more than that. This is not an insignificant achievement.

"Central nervous system disorders are a scourge because they are challenging to treat by their very nature. We have the potential to eliminate this problem, so an unmet need becomes a met need,"

Giroux now hopes to blast Kurve Therapeutics into a new growth period, teaming up with award-winning broker-dealer Rialto Markets' crowdfunding infrastructure and technology for its Regulation A+ offering:

"Following extensive work developing treatments and our CPD technology, we are ready to scale the company and grow our investor community.

"We plan to invest most of our proceeds into our final phase III clinical trials for intranasal insulin for mild cognitive impairment in Alzheimer’s. Kurve Therapeutics is ready for Phase III clinical trials in three separate disease states and is one Phase III study away from being eligible for FDA approval."

Caption: Rialto Markets CEO & Co-Founder Shari Noonan

Rialto Markets CEO and Co-founder Shari Noonan said: "Kurve Therapeutics' intranasal drug delivery technology has the potential to transform the lives of millions suffering from neurodegenerative diseases.

"This is a very exciting and important sector which needs this essential innovation, so we are delighted that Kurve Therapeutics chose to work with us to grow and scale."

Rialto Markets' has a capital raising infrastructure for Reg CF and Reg A+ equity crowdfunding as well as Reg D institutional investment offering. Alongside this, Rialto Markets has a pioneering secondary market alternative trading system (ATS) which empowers the buying and selling of shares in private companies or other private securities, which can operate similarly in a regulated framework and environment as a stock exchange does such as the Nasdaq and NYSE for public company trading.

This secondary trading ATS allows private companies and shareholders to potentially create liquidity and trading within a $7 trillion-dollar private securities market set to grow to $30 trillion by 2030, potentially enabling greater access to vital funding and private securities within a fully regulated environment.

Ends

_______________________________________________________________

Rialto Markets is a FINRA member Broker Dealer (Rialto Primary) and operates an alternative trading system (Rialto Secondary – Rialto MarketBoard™) for private securities including those issued as a Digital Asset Security. Rialto Primary supports companies issuing equity and debt securities through Reg A+, Reg CF, and Reg D exemptions. Rialto Markets is registered in all 50 states including those requiring a broker-dealer to issue Reg A+ securities 

Kurve Therapeutics Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, and device technology, our mission is to pave the way in treating complex CNS disorders, including Alzheimer’s disease, cognitive aging, Lewy body dementia, Parkinson’s disease, and ALS. The Kurve technology is featured in 18 peer-reviewed publications in leading medical journals. Kurve technology has been used in five double-blind placebo-controlled Phase II studies and is ready for Phase III with Alzheimer’s patients.

Rogers to Offer All-New iPhone 14, iPhone 14 Plus, iPhone 14 Pro, iPhone 14 Pro Max, Apple Watch Series 8, and AirPods Pro (2nd Generation)

The iPhone 14 lineup and AirPods Pro (2nd Generation) are available to pre-order starting today, and Apple Watch Series 8 available to order on September 16

TORONTO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Rogers will offer the most advanced iPhone lineup ever with iPhone 14, iPhone 14 Plus, iPhone 14 Pro and iPhone 14 Pro Max, all with a durable and sophisticated design, superfast 5G, impressive camera upgrades, and vital new safety capabilities; Apple Watch Series 8, with ground-breaking technology and performance; and the second generation of AirPods Pro, the most advanced AirPods yet.

iPhone 14 lineup and iPhone 14 Pro 
iPhone 14 and iPhone 14 Plus introduce new technologies and ground-breaking new safety capabilities, featuring two sizes — 6.1 inches and 6.7 inches.^[1] The powerful camera system brings impressive upgrades and huge improvements to low-light photos, thanks to the enhanced image pipeline, Photonic Engine. Offering stunning video quality, both models also include a new Action mode for incredibly stable video, and Cinematic mode, now available at 4K at 30fps and 4K at 24fps. New vital safety capabilities — Emergency SOS via satellite and Crash Detection — help connect iPhone users with emergency assistance when they need it most, and with the A15 Bionic chip with 5-core GPU, gorgeous Super Retina XDR display, amazing battery life, industry-leading durability features, and superfast 5G, this lineup is more advanced than ever before. iPhone 14 and iPhone 14 Plus come in five beautiful colours — midnight, blue, starlight, purple, and PRODUCT^(RED).^[2]

Powered by A16 Bionic, the fastest chip ever in a smartphone, iPhone 14 Pro and iPhone 14 Pro Max introduce intuitive new ways to experience iPhone, a new class of pro camera system, and ground-breaking new safety capabilities. Featuring the first-ever 48MP Main camera on iPhone, new Ultra Wide camera, Telephoto camera, and new TrueDepth front camera with autofocus, the pro camera system is even more advanced, and with Photonic Engine, represents the biggest camera leap ever. iPhone 14 Pro and iPhone 14 Pro Max also introduce a new interactive way to experience notifications and alerts with Dynamic Island, and the Always-On display. Available in 6.1-inch and 6.7- inch sizes in four gorgeous finishes — deep purple, gold, silver, and space black — iPhone 14 Pro and iPhone 14 Pro Max also include superfast 5G, Emergency SOS via satellite, and Crash Detection, all while offering all-day battery life. Customers will be able to pre-order all iPhone models on Friday September 9, with iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max availability on Friday, September 16, and Friday, October 7 for iPhone 14 Plus.

Apple Watch Series 8 
Apple Watch Series 8 and new Apple Watch SE bring ground-breaking technology and performance, and important safety innovations to the two best-selling smartwatches. Apple Watch Series 8 maintains the current beloved design with a large, Always-On Retina display, 18-hour battery life, and a new Low Power Mode that can extend battery life to reach up to 36 hours ^[3], while building on best-in-class health and safety features like the ECG app and Fall Detection by introducing temperature-sensing capabilities, retrospective ovulation estimates ^[4], and Crash Detection. Apple Watch Series 8 is available in two sizes, 41mm and 45mm, across a range of case finishes and colours including starlight, midnight, silver, and PRODUCT^(RED).^[2]

AirPods Pro (2nd Generation) 
The second generation of AirPods Pro unlock breakthrough audio performance, including major upgrades to Active Noise Cancellation and Transparency mode, all powered by the new H2 chip. With Personalized Spatial Audio, the AirPods Pro listening experience is even more immersive, and with Touch control, customers can now directly adjust volume with a quick swipe up or down on the stem. Users can enjoy up to six hours of listening time with Active Noise Cancellation, and up to 30 hours when using the case for additional charges. ^[5] Customers can order AirPods Pro (2nd Generation) online on Friday, September 9, with availability in stores on Friday, September 23.

Experience the power and performance of the Rogers 5G Network across the iPhone 14 lineup. For more details, including pricing and data plans, please visit rogers.com/iphone or fido.ca/iphone.

For more details on Apple products, please visit www.apple.com.

About Rogers
Rogers is a leading Canadian technology and media company that provides world-class communications services and entertainment to consumers and businesses on our award-winning networks. Our founder, Ted Rogers, purchased his first radio station, CHFI, in 1960. Today, we are dedicated to providing industry-leading wireless, cable, sports, and media to millions of customers across Canada. Our shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit: www.rogers.com or http://investors.rogers.com.

Clearwater River Dene Nation Upgrades Mobile App; Offers Even More Features and Updates to Band Members

CLEARWATER RIVER, Saskatchewan, Sept. 09, 2022 (GLOBE NEWSWIRE) -- The leadership of Clearwater River Dene Nation (CRDN) has released the first major implementation upgrade to their official mobile app, adding new functionality and redesigning the app experience.

The official CRDN app was first introduced in 2020, gradually offering development stage information on news, events, and other communication resource options to band members and the public. Due to the safety and health restrictions from the ongoing pandemic, the CRDN decided on implementing this much-needed vital and important communication tool to support our quest for providing information to our community.

The mobile App serves to provide a variety of communication options from Leadership to our admin programs departments to general information sharing with the membership of CRDN. Urgent notifications are sent directly to users’ phones in cases of emergency, or to distribute important updates regarding community support guidance and directions.

The CRDN app runs on the Communikit platform, developed by Aivia Inc. Communikit is Canada’s first mobile app platform designed specifically for Indigenous communities of interest to expand and maximize their communications options for their members.

The extensive technical and visual upgrade includes a new interface design, new posting functionality for administrators, the introduction of a tagging system for easily locating posts, and administrative analytics. The user system has been fully redeveloped to make it easier for users to sign up and access the app, recover their login credentials if they forget, and take advantage of their phone’s capacity and alert functionality included with the app.

“We continue to work with the Communikit team at Aivia Inc. to make the CRDN Communication App accommodating for our community participation and usage — the new version is more diverse for our users and makes it easier for our administrators to publish updates on the app,” explained Chief Teddy Clarke.

“Keeping our band members up to date on what is happening in the community is vital, for both on and off-reserve. Being able to send notifications directly out to our members removes a barrier and means we are able to get out urgent notices with accurate and precise information. The new update lets our administrators get notifications sent out with less effort.”

The new and improved CRDN mobile app is available for download on iOS and Android devices. Get the free app today and start keeping up with our Nation!

The Chief and Council of the Clearwater River Dene Nation are proud to offer this community resource moving forward with a new generational era, where our community can now have that grassroots connection while participating in the many positive trends and developments underway in our Nation.

Respectfully Yours,